Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease

The important role of monocytes and macrophages in diseases like cancer and atherosclerosis has started to get uncovered in the last decade. In addition, subsets of these cell types are believed to participate in the initiation and aggravation of several diseases including cancer and cardiovascular disease. For this reason, monocytes and macrophages have recently been identified as interesting targets for both diagnosis and treatment of the aforementioned pathologies. Compared with free therapeutic or imaging agents, nanoparticle formulations provide several advantages that improve the pharmacokinetics and bioavailability of these agents. In addition, the possibility of surface functionalization creates numerous ways to optimize nanoparticle delivery. Recent advances in nanomedicine have led to the development of multifunctional nanoparticles that allow simultaneous diagnosis and treatment of monocytes and macrophages with high specificity. Relying on the inherent ability of monocytes and macrophages to easily take up foreign particles, the use of nanoparticles provides a precious opportunity for the management of several inflammatory diseases.

[1]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[2]  J. Kjems,et al.  Chitosan/siRNA Nanoparticle-mediated TNF-α Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Jun Wang,et al.  Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma , 2011, Medical oncology.

[4]  A. Nardin,et al.  Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. , 2006, Current cancer drug targets.

[5]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[6]  P. Libby,et al.  The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models , 2008, Nature Reviews Immunology.

[7]  G. Randolph.  No Need to Coax Monocytes , 2011, Science.

[8]  T. Martin,et al.  Innate immunity in the lungs. , 2005, Proceedings of the American Thoracic Society.

[9]  Naomi J Halas,et al.  Nanoshell-enabled photothermal cancer therapy: impending clinical impact. , 2008, Accounts of chemical research.

[10]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[11]  G. Burmester,et al.  Cells of the synovium in rheumatoid arthritis. Macrophages , 2007, Arthritis research & therapy.

[12]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[13]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[14]  Jennifer Sturgis,et al.  A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. , 2007, Nano letters.

[15]  Nils Welsh,et al.  Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. , 2005, Diabetes.

[16]  M. Rekhter,et al.  Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. , 1995, The American journal of pathology.

[17]  K. Morimoto,et al.  Influence of Particle Size on the Distributions of Liposomes to Atherosclerotic Lesions in Mice , 2006, Drug development and industrial pharmacy.

[18]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[19]  Claudia Jakubzick,et al.  Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Leo M. Carlin,et al.  Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal , 2013, Cell.

[21]  R. Mebius,et al.  Structure and function of the spleen , 2005, Nature Reviews Immunology.

[22]  D. Hume,et al.  Unravelling mononuclear phagocyte heterogeneity , 2010, Nature Reviews Immunology.

[23]  Hong Ding,et al.  Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[24]  J. Ernst,et al.  Tuberculosis pathogenesis and immunity. , 2012, Annual review of pathology.

[25]  T. Sweeting,et al.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease , 2009, The Journal of experimental medicine.

[26]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[27]  M. McConnell,et al.  Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. , 2011, ACS nano.

[28]  Claudia Calcagno,et al.  Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. , 2008, Nano letters.

[29]  M. Khan,et al.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[31]  X. Zhang,et al.  Macrophage activation by endogenous danger signals , 2008, The Journal of pathology.

[32]  A. Mildner,et al.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. , 2013, Immunity.

[33]  J. Gaglia,et al.  Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. , 2011, The Journal of clinical investigation.

[34]  Zahi A Fayad,et al.  Multifunctional gold nanoparticles for diagnosis and therapy of disease. , 2013, Molecular pharmaceutics.

[35]  P. Barnes.  Alveolar Macrophages as Orchestrators of COPD , 2004, COPD.

[36]  Zahi A Fayad,et al.  Nanotechnology in Medical Imaging: Probe Design and Applications , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[37]  R. Good,et al.  Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. , 1966, Lancet.

[38]  Z. Fayad,et al.  Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality , 2013, NMR in biomedicine.

[39]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[40]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[41]  P. De Baetselier,et al.  SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis , 2013, The Journal of Nuclear Medicine.

[42]  S. Gordon,et al.  The role of macrophages in inflammatory bowel diseases , 2009, Expert Reviews in Molecular Medicine.

[43]  G. Meijer,et al.  Carcinoma origin dictates differential skewing of monocyte function , 2012, Oncoimmunology.

[44]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[45]  P. Conti,et al.  Target-specific delivery of peptide-based probes for PET imaging. , 2010, Advanced drug delivery reviews.

[46]  R. Curi,et al.  LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. , 2007, Atherosclerosis.

[47]  A. Koch,et al.  Macrophages and their products in rheumatoid arthritis , 2007, Current opinion in rheumatology.

[48]  Michael R. Elliott,et al.  Identification of a Novel Macrophage Phenotype That Develops in Response to Atherogenic Phospholipids via Nrf2 , 2010, Circulation research.

[49]  R. Weissleder,et al.  Detection of Macrophages in Aortic Aneurysms by Nanoparticle Positron Emission Tomography–Computed Tomography , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[50]  Luke Barron,et al.  Macrophages: Master Regulators of Inflammation and Fibrosis , 2010, Seminars in liver disease.

[51]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[52]  B. Passlick,et al.  Identification and characterization of a novel monocyte subpopulation in human peripheral blood. , 1989, Blood.

[53]  Ansuman T. Satpathy,et al.  Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. , 2012, Immunity.

[54]  E. Pamer,et al.  Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2 , 2006, Nature Immunology.

[55]  Z. Fayad,et al.  Nanomedical Theranostics in Cardiovascular Disease , 2011, Current Cardiovascular Imaging Reports.

[56]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[57]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[58]  M. Karsdal,et al.  Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. , 2011, Endocrine reviews.

[59]  P. Libby,et al.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions , 2007, The Journal of experimental medicine.

[60]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.

[61]  S. Blankenberg,et al.  CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-α levels , 2004, Thrombosis and Haemostasis.

[62]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[63]  R. Willette,et al.  Differential uptake of ferumoxtran‐10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: Critical determinants of atherosclerotic plaque labeling , 2005, Journal of magnetic resonance imaging : JMRI.

[64]  M. Nahrendorf,et al.  Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.

[65]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[66]  Sanyog Jain,et al.  Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. , 2004, International journal of pharmaceutics.

[67]  R. Weissleder,et al.  Cell-specific targeting of nanoparticles by multivalent attachment of small molecules , 2005, Nature Biotechnology.

[68]  S. Kawakami,et al.  Enhanced Anti-Inflammation of Inhaled Dexamethasone Palmitate Using Mannosylated Liposomes in an Endotoxin-Induced Lung Inflammation Model , 2008, Molecular Pharmacology.

[69]  A. Gerbes,et al.  Role of Kupffer cells in host defense and liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[70]  William D Rooney,et al.  Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and Central Nervous System Inflammatory Pathologies, a Review , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[71]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[72]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[73]  J. Kjems,et al.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[75]  James R Baker,et al.  Dendrimer-based nanoparticles for cancer therapy. , 2009, Hematology. American Society of Hematology. Education Program.

[76]  Subinoy Rana,et al.  Surface functionalization of nanoparticles for nanomedicine. , 2012, Chemical Society reviews.

[77]  A. Constantin,et al.  Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. , 2013, Rheumatology.

[78]  Peter Libby,et al.  Inflammation and cellular immune responses in abdominal aortic aneurysms. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[79]  M. Wendland,et al.  MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles , 2011, Clinical Cancer Research.

[80]  J. Suttles,et al.  Macrophages Sequentially Change Their Functional Phenotype in Response to Changes in Microenvironmental Influences1 , 2005, The Journal of Immunology.

[81]  D. Dormont,et al.  Macrophage activation switching: an asset for the resolution of inflammation , 2005, Clinical and experimental immunology.

[82]  V. Fuster,et al.  Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. , 2010, Molecular pharmaceutics.

[83]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[84]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[85]  Osman Muhammad,et al.  QUANTUM DOTS ARE PHAGOCYTIZED BY MACROPHAGES AND COLOCALIZE WITH EXPERIMENTAL GLIOMAS , 2007, Neurosurgery.

[86]  I. Fidler,et al.  Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. , 1980, Cancer research.

[87]  L. Sibley,et al.  Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis , 2005, The Journal of experimental medicine.

[88]  F. Tacke,et al.  Migratory fate and differentiation of blood monocyte subsets. , 2006, Immunobiology.

[89]  G. Golomb,et al.  Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[90]  P. Libby,et al.  Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease , 2006, Proceedings of the National Academy of Sciences.

[91]  Steffen Jung,et al.  Monocytes: subsets, origins, fates and functions , 2010, Current opinion in hematology.

[92]  Zahi A. Fayad,et al.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis , 2011, Nature Reviews Drug Discovery.

[93]  L. Minasian,et al.  CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. , 1995, Blood.

[94]  C. Weber,et al.  Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.

[95]  S. Cryan,et al.  Targeted Liposomal Drug Delivery to Monocytes and Macrophages , 2010, Journal of drug delivery.

[96]  David A. Hume,et al.  Macrophages as APC and the Dendritic Cell Myth , 2008, The Journal of Immunology.

[97]  A. Tiwary,et al.  Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation , 2008, Acta pharmaceutica.

[98]  R. Weissleder,et al.  89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. , 2011, Bioconjugate chemistry.

[99]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[100]  R. Beelen,et al.  Macrophages in skin injury and repair. , 2011, Immunobiology.

[101]  S. Blankenberg,et al.  CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. , 2004, Thrombosis and haemostasis.

[102]  Daniel G. Anderson,et al.  Origins of tumor-associated macrophages and neutrophils , 2012, Proceedings of the National Academy of Sciences.

[103]  H. Gendelman,et al.  Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery , 2006, Journal of leukocyte biology.

[104]  Schraibman Ig,et al.  Letter: Intravenous regional sympathetic block with guanethidine. , 1974 .

[105]  Claudia Mauri,et al.  Cells of the synovium in rheumatoid arthritis , 2007 .

[106]  Ralph Weissleder,et al.  Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.

[107]  P. Libby,et al.  Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites , 2009, Science.

[108]  Ralph Weissleder,et al.  A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. , 2010, Small.

[109]  R. Weissleder,et al.  Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging , 2012, Nature Immunology.

[110]  Claudia Calcagno,et al.  Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. , 2012, Methods in enzymology.

[111]  Ralph Weissleder,et al.  Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. , 2009, Neoplasia.

[112]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[113]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[114]  A. Ben-Baruch,et al.  The inflammatory chemokines CCL2 and CCL5 in breast cancer. , 2008, Cancer letters.

[115]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[117]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[118]  Thommey P. Thomas,et al.  Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. , 2011, Arthritis and rheumatism.